BridgeBio Pharma
BBIO
76.03
-2.15
-2.75%
BridgeBio Pharma
US · BBIO
#1254 by market cap
Listed 2019
76.03
-2.15
-2.75%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q4).
- Total institutional ownership rose 0.6 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 100.89% +0.58pp
- Institutions
- 578 -2
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund60.30%
Hedge Fund25.61%
VC/PE Fund7.59%
Individual/Insider3.95%
Public Company3.16%
Private Company2.05%
Sovereign Wealth Fund0.87%
Government Pension Fund0.67%
Endowment Fund0.32%
Insurance Company0.23%
Top holders as of 2026-09-30
Farallon Capital Management, L.L.C.
7.31% · 14.25M sh
Janus Henderson Group plc
7.24% · 14.11M sh
BlackRock
5.33% · 10.39M sh
Viking Global Investors LP
5.03% · 9.79M sh
Wellington Management Group
4.86% · 9.46M sh
Vanguard Capital Management, LLC
4.64% · 9.04M sh
KKR & Co. Inc.
4.24% · 8.26M sh
Vanguard Portfolio Management, LLC
3.84% · 7.49M sh
Neil Kumar
2.61% · 5.09M sh
Two Sigma Investments, LP
2.42% · 4.72M sh
State Street Global Advisors
2.56% · 4.98M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Neil Kumar | Chief Executive Officer | 2.61% |
| Charles Homcy | Co-Founder, Chairman of Pharmaceuticals & Lead Director | 0.47% |
| Frank McCormick | Co-Founder, Chairman of Oncology & Director | 0.39% |
| Thomas Trimarchi | CFO & President | 0.16% |
| Ali Satvat | Independent Director | 0.08% |
| Maricel Apuli | Chief Accounting Officer | 0.06% |
| Brian Stephenson | Former Chief Financial Officer | 0.05% |
| James Momtazee | Independent Director | 0.05% |
| Andrew Lo | Independent Director | 0.03% |
| Wen-Chaun Lo | Independent Director | 0.03% |
| Douglas Dachille | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-29 | Maricel Apuli | Chief Accounting Officer | Automatic Disposition | -2,000 | $72.85 |
| 2026-09-16 | Neil Kumar | Chief Executive Officer | Automatic Disposition | -10,000 | $69.01–69.57 |
| 2026-08-18 | Neil Kumar | Chief Executive Officer | Automatic Disposition | -44,980 | $81.15–85.65 |
| 2026-08-17 | Neil Kumar | Chief Executive Officer | Intent to Sell (Form 144) | -34,980 | $79.89 |
| 2026-08-16 | Randal Scott | Former Independent Director | Intent to Sell (Form 144) | -21,501 | $79.86 |
| 2026-08-15 | Neil Kumar | Chief Executive Officer | Derivative Exercise and Sale | -36,237 | $79.86 |
| 2026-08-15 | Neil Kumar | Chief Executive Officer | Derivative Exercise and Retained | +34,980 | -- |
| 2026-08-15 | Thomas Trimarchi | CFO & President | Sale to Issuer | -22,781 | $79.86 |
| 2026-08-15 | Maricel Apuli | Chief Accounting Officer | Sale to Issuer | -4,714 | $79.86 |
| 2026-07-29 | Maricel Apuli | Chief Accounting Officer | Automatic Disposition | -2,000 | $80.06 |
| 2026-07-08 | Jennifer Cook | Independent Director | Derivative Exercise and Sale | -148,589 | $8.45–90.00 |
| 2026-07-08 | Andrea Ellis | Independent Director | Derivative Exercise and Sale | -17,167 | $16.75–84.00 |
| 2026-06-23 | Randal Scott | Former Independent Director | Intent to Sell (Form 144) | -2,196 | $68.63 |
| 2026-06-23 | Jennifer Cook | Independent Director | Derivative Exercise and Sale | -37,167 | $8.45–70.00 |
| 2026-06-22 | Jennifer Cook | Independent Director | Automatic Disposition | -2,196 | $68.57 |
| 2026-06-22 | Hannah Valantine | Independent Director | Automatic Disposition | -2,196 | $68.57 |
| 2026-06-21 | Charles Homcy | Co-Founder, Chairman of Pharmaceuticals & Lead Director | Other Acquisition | +3,990 | -- |
| 2026-06-21 | Charles Homcy | Co-Founder, Chairman of Pharmaceuticals & Lead Director | Other Derivative Acquisition | +5,277 | $68.92 |
| 2026-06-21 | Fred Hassan | Lead Independent Director | Other Acquisition | +3,990 | -- |
| 2026-06-21 | Fred Hassan | Lead Independent Director | Other Derivative Acquisition | +5,277 | $68.92 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:24 · For reference only, not investment advice and not tailored to your situation.
BridgeBio Pharma discussion 0 comments